



October 21, 2014

Mitsubishi Chemical Holdings Corporation

**Mitsubishi Tanabe Pharma Announces a Revision
to the Consolidated Financial Forecasts
for Fiscal Year Ending March 31, 2015**

Mitsubishi Chemical Holdings Corporation (Head office: Chiyoda-ku, Tokyo; President: Yoshimitsu Kobayashi) announces that its consolidated subsidiary, Mitsubishi Tanabe Pharma Corporation (Head office: Chuo-ku, Osaka; President: Masayuki Mitsuka) announced today a revision to the consolidated financial forecasts for the fiscal year ending March 31, 2015, which were announced on May 8, 2014. Please refer to the attached press release for details.

For further information, please contact:

Public Relations and Investor Relations Office
Mitsubishi Chemical Holdings Corporation
TEL: [+81] (0)3-6748-7140

October 21, 2014

Press release:

Mitsubishi Tanabe Pharma Corporation

**Revisions to Consolidated Financial Forecasts
for Fiscal Year Ending March 31, 2015**

Osaka, Japan, October 21, 2014 --- Mitsubishi Tanabe Pharma Corporation (Head office: Chuo-ku, Osaka, President and Representative Director, CEO: Mitsuka Masayuki) announced today revisions to the consolidated financial forecasts for 2Q and full-year of the fiscal year ending March 31, 2015, which were announced on May 8, 2014.

1. Revised consolidated financial forecasts for 2Q of the fiscal year ending March 31, 2015 (April 1, 2014 to September 30, 2014)

| | Sales | Operating income | Ordinary income | Net income | Net income per share |
|--|----------------------------|---------------------------|---------------------------|---------------------------|----------------------|
| Previous forecast (A) | Millions of yen 201,000 | Millions of yen 29,500 | Millions of yen 30,500 | Millions of yen 21,000 | Yen 37.43 |
| Revised forecast (B) | 198,500 | 34,500 | 35,000 | 32,500 | 57.93 |
| Difference (B-A) | (2,500) | 5,000 | 4,500 | 11,500 | — |
| Percentage change (%) | (1.2) | 16.9 | 14.8 | 54.8 | — |
| (Reference) Results in the same period of the previous fiscal year | 202,834 | 30,459 | 32,198 | 28,544 | 50.88 |

2. Revised consolidated financial forecasts for full-year of the fiscal year ending March 31, 2015 (April 1, 2014 to March 31, 2015)

| | Sales | Operating income | Ordinary income | Net income | Net income per share |
|--|----------------------------|---------------------------|---------------------------|---------------------------|----------------------|
| Previous forecast (A) | Millions of yen 409,000 | Millions of yen 60,000 | Millions of yen 61,500 | Millions of yen 40,500 | Yen 72.19 |
| Revised forecast (B) | 406,000 | 60,000 | 61,500 | 40,500 | 72.19 |
| Difference (B-A) | (3,000) | 0 | 0 | 0 | — |
| Percentage change (%) | (0.7) | 0.0 | 0.0 | 0.0 | — |
| (Reference) Results in the same period of the previous fiscal year | 412,675 | 59,119 | 61,873 | 45,393 | 80.92 |

3. Reason for revision

In the 2Q of the fiscal year, growth in the influence of generics exceeded expectations, and as a result sales of long-listed drugs declined. Due in part to this decline, net sales are not expected to reach the level of the previously announced forecast.

In profits, due to reductions in expenses and to the recording of certain expenses after the close of the period, SG&A expenses for the 2Q declined. In addition, gain on the sale of the former Nihonbashi Building was recorded as extraordinary income. Consequently, operating income, ordinary income, and net income all exceeded the previously announced forecasts.

For the full fiscal year, the influence of generics is expected to continue to expand, and as a result the Company will make a downward revision to its forecast for net sales. However, SG&A expenses are expected to decrease due to a reduction in expenses, and consequently the forecasts for operating income and ordinary income are unchanged, at ¥60.0 billion and ¥61.5 billion, respectively.

Moreover, in the second half of the fiscal year, the Company expects to record extraordinary losses due to the reorganization of manufacturing bases accompanying structural reforms, which the Company is currently accelerating. The forecast for net income is unchanged, at ¥40.5 billion.

Note: The above results forecasts reflect judgments and assumptions that are based on information available at the present point in time. For any of a number of reasons, actual results might differ materially from these forecasts.